Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trolamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trolamine SCHEMBL2390784 | 0.98 | FDPS (0.39) | TDP1FDPSBLMALDH1A1KDM4E | |
| Trolamine SCHEMBL3283293 | 0.87 | CA5A (0.38) | TDP1ALDH1A1KDM4ECA5ACA5B | |
| Trolamine SCHEMBL2869748 | 0.87 | FDPS (0.53) | TDP1FDPSBLMKDM4ESMN1; SMN2 | |
| Trolamine SCHEMBL2396169 | 0.82 | CA5A (0.47) | TDP1ALDH1A1KDM4ECA5ACA5B | |
| Trolamine SCHEMBL725388 | 0.82 | CA5A (0.47) | TDP1ALDH1A1KDM4ECA5ACA5B | |
| Trolamine SCHEMBL9299420 | 0.80 | CA5A (0.44) | TDP1ALDH1A1KDM4ECA5ACA5B | |
| Trolamine SCHEMBL28050292 | 0.80 | CA5A (0.44) | TDP1ALDH1A1KDM4ECA5ACA5B | |
| Triphosphate SCHEMBL7796776 | 0.79 | FDPS (0.41) | TDP1FDPSBLMKDM4ESMN1; SMN2 | |
| Trolamine SCHEMBL9300209 | 0.78 | CA5A (0.42) | TDP1ALDH1A1KDM4ECA5ACA5B | |
| Pyrophosphoric Acid SCHEMBL8931250 | 0.78 | FDPS (0.59) | TDP1FDPSBLMCA5ACA5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805730-A1 | Nitric oxide donor for the treatment of chronic fatigue syndrome | Bergen Teknologioverforing AS (NO) | 2014-11-26 | — | — | EP | claimed |
| US-20080317679-A1 | FOAMABLE COMPOSITIONS AND KITS COMPRISING ONE OR MORE OF A CHANNEL AGENT, A CHOLINERGIC AGENT, A NITRIC OXIDE DONOR, AND RELATED AGENTS AND THEIR USES | FOAMIX LTD. (IL) | 2008-12-25 | — | — | US | claimed |
| JP-2008540509-A | — | — | 2008-11-20 | — | — | JP | claimed |
| WO-2008110872-A2 | FOAMABLE COMPOSITIONS AND KITS COMPRISING ONE OR MORE OF A CHANNEL AGENT, A CHOLINERGIC AGENT, A NITRIC OXIDE DONOR, AND RELATED AGENTS AND THEIR USES | FOAMIX LTD. (US) | 2008-09-18 | — | — | WO | claimed |
| EP-1919448-A2 | VASOACTIVE KIT AND COMPOSITION AND USES THEREOF | Foamix Ltd. (IL) | 2008-05-14 | — | — | EP | claimed |
| WO-2007023396-A2 | VASOACTIVE KIT AND COMPOSITION AND USES THEREOF | FOAMIX LTD. (US) | 2007-03-01 | — | — | WO | claimed |
| US-20050271596-A1 | Vasoactive kit and composition and uses thereof | FOAMIX LTD. | 2005-12-08 | — | — | US | claimed |
| EP-4277592-A1 | TOPICAL COMPOSITION | Liliger Ltd (IL) | 2023-11-22 | — | — | EP | disclosed |
| US-20230355500-A1 | TOPICAL COMPOSITION | LILIGER LTD (IL) | 2023-11-09 | — | — | US | disclosed |
| CN-116685302-A | Topical compositions | 利勒格有限公司 | 2023-09-01 | — | — | CN | disclosed |
| US-11433025-B2 | Oil foamable carriers and formulations | VYNE THERAPEUTICS INC. (US) | 2022-09-06 | — | — | US | disclosed |
| WO-2022153308-A1 | TOPICAL COMPOSITION | RICH PSC LTD. (IL) | 2022-07-21 | — | — | WO | disclosed |
| US-20210386944-A1 | GAS-EVOLVING COMPOSITIONS AND CONTAINER AND DELIVERY SYSTEMS | SANOTIZE RESEARCH DEVELOPMENT CORP. (CA) | 2021-12-16 | — | — | US | disclosed |
| US-4834979-A | Medical bandage for administering beneficial drug | ALZA CORPORATION (US) | 1989-05-30 | — | — | US | disclosed |
| US-4812313-A | Method for lessening the incidence of anginal attacks | ALZA CORPORATION (US) | 1989-03-14 | — | — | US | disclosed |
| US-4725272-A | Novel bandage for administering beneficial drug | ALZA CORPORATION (US) | 1988-02-16 | — | — | US | disclosed |
| US-4704119-A | Method comprising transdermal and buccal treatment of angina | ALZA CORPORATION (US) | 1987-11-03 | — | — | US | disclosed |
| US-4661105-A | Medical bandage for administering vasodilator drug | ALZA CORPORATION (US) | 1987-04-28 | — | — | US | disclosed |
| US-4650484-A | Method for treating ischemic conditions | ALZA CORPORATION (US) | 1987-03-17 | — | — | US | disclosed |
| US-4486193-A | Method for treating ischemic conditions by administering drug by two routes | ALZA CORPORATION (US) | 1984-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433025-B2 | Oil foamable carriers and formulations | LIPA, PTGER1, TTPA | TDP1 3437/4885FDPS 446/4885BLM 543/4885 |
| US-20210386944-A1 | GAS-EVOLVING COMPOSITIONS AND CONTAINER AND DELIVERY SYSTEMS | GMPS, SQOR, GSS | TDP1 2909/4885FDPS 875/4885BLM 2109/4885 |
| US-20230355500-A1 | TOPICAL COMPOSITION | NOS1, NOS3, NOS2 | TDP1 446/4885FDPS 1984/4885BLM 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.